Cargando…
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917771/ https://www.ncbi.nlm.nih.gov/pubmed/36769831 http://dx.doi.org/10.3390/jcm12031183 |
_version_ | 1784886447607644160 |
---|---|
author | Bordeau, Karl Michalet, Morgan Keskes, Aïcha Valdenaire, Simon Debuire, Pierre Cantaloube, Marie Cabaillé, Morgane Jacot, William Draghici, Roxana Demontoy, Sylvain Quantin, Xavier Ychou, Marc Assenat, Eric Mazard, Thibault Gauthier, Ludovic Dupuy, Marie Guiu, Boris Bourgier, Céline Aillères, Norbert Fenoglietto, Pascal Azria, David Riou, Olivier |
author_facet | Bordeau, Karl Michalet, Morgan Keskes, Aïcha Valdenaire, Simon Debuire, Pierre Cantaloube, Marie Cabaillé, Morgane Jacot, William Draghici, Roxana Demontoy, Sylvain Quantin, Xavier Ychou, Marc Assenat, Eric Mazard, Thibault Gauthier, Ludovic Dupuy, Marie Guiu, Boris Bourgier, Céline Aillères, Norbert Fenoglietto, Pascal Azria, David Riou, Olivier |
author_sort | Bordeau, Karl |
collection | PubMed |
description | Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were included in this prospective registry study. Stereotactic MRgRT indication was confirmed by multidisciplinary specialized tumor boards. The primary endpoints were acute and late toxicities. The secondary endpoints were survival outcomes (local control, overall survival (OS), disease-free survival, intrahepatic relapse-free survival). Twenty-six consecutive patients were treated for thirty-one liver metastases between October 2019 and April 2022. The median prescribed dose was 50 Gy (40–60) in 5 fractions. No severe acute MRgRT-related toxicity was noted. Acute and late gastrointestinal and liver toxicities were low and mostly unrelated to MRgRT. Only 5 lesions (16.1%) required daily adaptation because of the proximity of organs at risk (OAR). With a median follow-up time of 17.3 months since MRgRT completion, the median OS, 1-year OS and 2-year OS rates were 21.7 months, 83.1% (95% CI: 55.3–94.4%) and 41.6% (95% CI: 13.5–68.1%), respectively, from MRgRT completion. The local control at 6 months, 1 year and 2 years was 90.9% (95% CI: 68.3–97.7%). To our knowledge, we report the largest series of stereotactic MRgRT for liver metastases. The treatment was well-tolerated and achieved a high LC rate. Distant relapse remains a challenge in this population. |
format | Online Article Text |
id | pubmed-9917771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99177712023-02-11 Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study Bordeau, Karl Michalet, Morgan Keskes, Aïcha Valdenaire, Simon Debuire, Pierre Cantaloube, Marie Cabaillé, Morgane Jacot, William Draghici, Roxana Demontoy, Sylvain Quantin, Xavier Ychou, Marc Assenat, Eric Mazard, Thibault Gauthier, Ludovic Dupuy, Marie Guiu, Boris Bourgier, Céline Aillères, Norbert Fenoglietto, Pascal Azria, David Riou, Olivier J Clin Med Article Liver stereotactic body radiotherapy (SBRT) is a local treatment that provides good local control and low toxicity. We present the first clinical results from our prospective registry of stereotactic MR-guided radiotherapy (MRgRT) for liver metastases. All patients treated for liver metastases were included in this prospective registry study. Stereotactic MRgRT indication was confirmed by multidisciplinary specialized tumor boards. The primary endpoints were acute and late toxicities. The secondary endpoints were survival outcomes (local control, overall survival (OS), disease-free survival, intrahepatic relapse-free survival). Twenty-six consecutive patients were treated for thirty-one liver metastases between October 2019 and April 2022. The median prescribed dose was 50 Gy (40–60) in 5 fractions. No severe acute MRgRT-related toxicity was noted. Acute and late gastrointestinal and liver toxicities were low and mostly unrelated to MRgRT. Only 5 lesions (16.1%) required daily adaptation because of the proximity of organs at risk (OAR). With a median follow-up time of 17.3 months since MRgRT completion, the median OS, 1-year OS and 2-year OS rates were 21.7 months, 83.1% (95% CI: 55.3–94.4%) and 41.6% (95% CI: 13.5–68.1%), respectively, from MRgRT completion. The local control at 6 months, 1 year and 2 years was 90.9% (95% CI: 68.3–97.7%). To our knowledge, we report the largest series of stereotactic MRgRT for liver metastases. The treatment was well-tolerated and achieved a high LC rate. Distant relapse remains a challenge in this population. MDPI 2023-02-02 /pmc/articles/PMC9917771/ /pubmed/36769831 http://dx.doi.org/10.3390/jcm12031183 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bordeau, Karl Michalet, Morgan Keskes, Aïcha Valdenaire, Simon Debuire, Pierre Cantaloube, Marie Cabaillé, Morgane Jacot, William Draghici, Roxana Demontoy, Sylvain Quantin, Xavier Ychou, Marc Assenat, Eric Mazard, Thibault Gauthier, Ludovic Dupuy, Marie Guiu, Boris Bourgier, Céline Aillères, Norbert Fenoglietto, Pascal Azria, David Riou, Olivier Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study |
title | Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study |
title_full | Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study |
title_fullStr | Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study |
title_full_unstemmed | Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study |
title_short | Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study |
title_sort | stereotactic mr-guided radiotherapy for liver metastases: first results of the montpellier prospective registry study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917771/ https://www.ncbi.nlm.nih.gov/pubmed/36769831 http://dx.doi.org/10.3390/jcm12031183 |
work_keys_str_mv | AT bordeaukarl stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT michaletmorgan stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT keskesaicha stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT valdenairesimon stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT debuirepierre stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT cantaloubemarie stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT cabaillemorgane stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT jacotwilliam stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT draghiciroxana stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT demontoysylvain stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT quantinxavier stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT ychoumarc stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT assenateric stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT mazardthibault stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT gauthierludovic stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT dupuymarie stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT guiuboris stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT bourgierceline stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT ailleresnorbert stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT fenogliettopascal stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT azriadavid stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy AT riouolivier stereotacticmrguidedradiotherapyforlivermetastasesfirstresultsofthemontpellierprospectiveregistrystudy |